ZURA — Zura Bio Limited Class A Ordinary Shares

Zura Bio Limited Class A Ordinary Shares (ZURA) is a biotechnology company listed on NASDAQ. It is led by Sandeep Chidambar Kulkarni M.D., based in 1489 W. Warm Springs Road, Henderson, NV, United States, 89014, with about 40 employees. Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Net income was -$51.5M. ZURA currently screens at market cap $343.5M.

Use this ZURA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ZURA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ZURA SEC filings page. Lician reads the product cache first so this HTML stays unique to Zura Bio Limited Class A Ordinary Shares even when a live quote feed is slow.